# Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer

> **NCT02226276** · NA · ACTIVE_NOT_RECRUITING · sponsor: **City of Hope Medical Center** · enrollment: 10 (actual)

## Conditions studied

- Bone Metastases
- HER2-positive Breast Cancer
- Liver Metastases
- Lung Metastases
- Recurrent Breast Cancer
- Soft Tissue Metastases
- Stage IV Breast Cancer

## Interventions

- **RADIATION:** fludeoxyglucose F 18
- **PROCEDURE:** positron emission tomography
- **PROCEDURE:** computed tomography
- **BIOLOGICAL:** trastuzumab
- **RADIATION:** copper Cu 64-DOTA-trastuzumab
- **PROCEDURE:** positron emission tomography
- **BIOLOGICAL:** ado-trastuzumab emtansine
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT02226276
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2015-01-07
- **Primary completion:** 2021-12-07
- **Final completion:** 2026-09-29
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2026-02-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02226276

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02226276, "Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02226276. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*